Progression-Free Survival (PFS)

Studied in DESTINY-Gastric01,

Median PFS of more than 5 months with ENHERTU1,2

Progression-free survival in the ENHERTU arm and in the irinotecan or paclitaxel arm1,2

ENHERTU progression-free survival vs chemotherapy ENHERTU progression-free survival vs chemotherapy
  • DESTINY-Gastric01 studied 188 adult patients with HER2+ aGC who had received ≥2 prior lines of treatment, including a trastuzumab-based regimen
  • PFS was not formally tested for statistical significance
  • DESTINY-Gastric01 studied 188 adult patients with HER2+ aGC who had received ≥2 prior lines of treatment, including a trastuzumab-based regimen
  • 53% reduction in risk of progession or death with ENHERTU vs irinotecan or paclitaxel1
  • (HR=0.47; 95% CI: 0.31, 0.71)

  • PFS was not formally tested for statistical significance

CI, confidence interval; HR, hazard ratio.

Ready to learn more about ENHERTU?